Purpose

Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with pembrolizumab. The goals of this study are to learn about: - The safety of the study treatment when given with standard treatment and if people tolerate it - The number of people who have the cancer respond (cancer gets smaller or goes away) with the new study treatment when given with standard treatment.

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

The main inclusion criteria include but are not limited to the following: - Has histologically documented urothelial carcinoma (UC) that is locally advanced and unresectable or metastatic - Must provide a newly obtained or archival tumor tissue sample (core or excisional biopsy) - Must not have received prior systemic therapy for locally advanced or metastatic UC - If infected with Human Immunodeficiency Virus (HIV), has well controlled HIV on antiretroviral therapy - If positive for hepatitis B surface antigen, has received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and has undetectable HBV viral load before randomization - If participant has a history of hepatitis C virus (HCV), has undetectable HCV viral load before randomization

Exclusion Criteria

The main exclusion criteria include but are not limited to the following: - Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing - Has active keratitis or corneal ulcerations - Has active inflammatory bowel disease requiring immunosuppressive medication, or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea) - Has uncontrolled, significant cardiovascular disease or cerebrovascular disease within the 6 months preceding study intervention - Has a history of uncontrolled diabetes - Has pleural effusion, ascites, and/or pericardial effusion that are symptomatic or require repeated drainage - Has active autoimmune disease that has required systemic treatment in the past 2 years - Has known additional malignancy that is progressing or has required active treatment within the past 2 years - Has known active central nervous system metastases and/or carcinomatous meningitis - Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids, or has current pneumonitis/interstitial lung disease - Has an active infection requiring systemic therapy - If infected with HIV, has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease - Has concurrent active HBV and HCV infection - Has a history of stem cell/solid organ transplant

Study Design

Phase
Phase 1/Phase 2
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Arm A: MK-3120 + Enfortumab Vedotin (EV) + Pembrolizumab
Participants will receive MK-3120 administered intravenously on Day 1 and Day 8 of each 3-week cycle and EV administered intravenously on Day 1 and Day 8 of each 3-week cycle until documented disease progression or any other discontinuation criterion is met and Pembrolizumab 200 mg administered intravenously on Day 1 of each 3-week cycle for up to 35 cycles (~2 years).
  • Drug: MK-3120
    Administered via intravenous (IV) infusion on day 1 and day 8 of each 3-week cycle
  • Drug: EV
    Administered via IV infusion on day 1 and day 8 of each 3-week cycle
    Other names:
    • AGS 22M6E
    • AGS-22CE
  • Biological: Pembrolizumab
    Administered via IV infusion on day 1 of each 3-week cycle
    Other names:
    • MK-3475
    • KEYTRUDA®
  • Drug: Rescue Medication
    Participants receive rescue medication at the investigator's discretion, per approved product label. Recommended rescue medication is Granulocyte Colony-Stimulating Factor (G-CSF).

Recruiting Locations

UCSF Medical Center at Mission Bay ( Site 5044)
San Francisco, California 94158
Contact:
Study Coordinator
415-699-7286

Cleveland Clinic Taussig Cancer ( Site 5036)
Cleveland, Ohio 44195
Contact:
Study Coordinator
216-444-8311

Huntsman Cancer Institute ( Site 5041)
Salt Lake City, Utah 84112-5550
Contact:
Study Coordinator
801-585-0155

More Details

Status
Recruiting
Sponsor
Merck Sharp & Dohme LLC

Study Contact

Toll Free Number
1-888-577-8839
Trialsites@msd.com

Detailed Description

This is a substudy of the master protocol MK-3475-U04 (KEYMAKER-U04)

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.